Ombre

Ombre is a healthcare startup that aims to revolutionize personalized gut health solutions for chronic disease prevention. Founded in 2016, Ombre provides a microbiome testing kit designed to offer personalized probiotics and microbiome analysis. The kit features a subscription-based, customized testing of the microbiome, along with tailored probiotics created specifically for each individual. This innovative approach aims to provide insights that can aid in the prevention of chronic diseases such as obesity, cystic fibrosis, and Alzheimer's, allowing users to address the underlying causes of gut problems.

Ombre recently secured a $4.00M Seed Round investment on 15 February 2022 from Relevance Ventures. This injection of capital will likely bolster the company's efforts in research and development, as well as market expansion. Ombre's commitment to leveraging microbiome data for personalized health solutions makes it a compelling investment opportunity in the rapidly growing health tech sector. The company's focus on preventative health measures aligns with current trends and the increasing demand for personalized healthcare solutions. As personalized medicine continues to gain traction, Ombre's innovative approach to gut health has the potential to disrupt the traditional healthcare landscape and make a meaningful impact on disease prevention and management.